ANAPTYSBIO, INC. Operating Lease, Payments
ANAPTYSBIO, INC. (ANAB) reported Operating Lease, Payments of $1.29 million for the 6-month period ending 2026-06-30, per its 10-KT filed 2026-09-21.
Financial Statements › Cash Flow › Other Cash Flow Items
us-gaap:OperatingLeasePayments · last filed 2026-09-21
- ANAPTYSBIO, INC. operating lease, payments for the quarter ending 2026-06-30 was $1.29M, a 3.03% increase year-over-year.
- ANAPTYSBIO, INC. operating lease, payments for the quarter ending 2026-03-31 was $639.00, a 3.06% increase year-over-year.
- ANAPTYSBIO, INC. operating lease, payments for the quarter ending 2025-12-31 was $639.00K, a 3.06% increase year-over-year.
- ANAPTYSBIO, INC. operating lease, payments for the quarter ending 2025-09-30 was $639.00K, a 3.06% increase year-over-year.
- ANAPTYSBIO, INC. operating lease, payments for fiscal 2025 was $2.53M, a 3.01% increase from fiscal 2024.
- ANAPTYSBIO, INC. operating lease, payments for fiscal 2024 was $2.46M, a 102875.69% increase from fiscal 2023.
- ANAPTYSBIO, INC. operating lease, payments for fiscal 2023 was $2.39K, a 99.90% decline from fiscal 2022.
- ANAPTYSBIO, INC. operating lease, payments for fiscal 2022 was $2.32M, a 228.51% increase from fiscal 2021.
| Period end | Operating Lease, Payments 3 month | Operating Lease, Payments 3 month as first filed | Operating Lease, Payments 6 month | Operating Lease, Payments 9 month | Operating Lease, Payments 12 month | Operating Lease, Payments 12 month as first filed |
|---|---|---|---|---|---|---|
| 2026-06-30 | $1.29M derived: 10-KT 6 month − 10-Q 3 month · filed 2026-09-21 | $1.29M 10-KT · filed 2026-09-21 | $1.93M derived: sum of 3 quarters · filed 2026-09-21 | $2.57M derived: sum of 4 quarters · filed 2026-09-21 | ||
| 2026-03-31 | $639.00 10-Q · filed 2026-05-12 | $639.64K derived: sum of 2 quarters · filed 2026-09-21 | $1.28M derived: sum of 3 quarters · filed 2026-09-21 | $2.53M derived: sum of 4 quarters · filed 2026-09-21 | ||
| 2025-12-31 | $639.00K derived: 10-KT 12 month − 10-Q 9 month · filed 2026-09-21 | $1.28M derived: sum of 2 quarters · filed 2026-09-21 | $2.53M derived: sum of 3 quarters · filed 2026-09-21 | $2.53M 10-KT · filed 2026-09-21 | $2.53K 10-K · filed 2026-03-03 | |
| 2025-09-30 | $639.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $1.89M derived: sum of 2 quarters · filed 2025-11-04 | $1.89M 10-Q · filed 2025-11-04 | $2.51M derived: sum of 4 quarters · filed 2026-09-21 | ||
| 2025-06-30 | $1.25M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | $1.25M 10-Q · filed 2025-08-06 | $1.87M derived: sum of 3 quarters · filed 2026-09-21 | $2.49M derived: sum of 4 quarters · filed 2026-09-21 | ||
| 2025-03-31 | $620.00 10-Q · filed 2026-05-12 | $620.00K 10-Q · filed 2025-05-05 | $620.62K derived: sum of 2 quarters · filed 2026-09-21 | $1.24M derived: sum of 3 quarters · filed 2026-09-21 | $1.86M derived: sum of 4 quarters · filed 2026-09-21 | |
| 2024-12-31 | $620.00K derived: 10-KT 12 month − 10-Q 9 month · filed 2026-09-21 | $1.24M derived: sum of 2 quarters · filed 2026-09-21 | $1.85M derived: sum of 3 quarters · filed 2026-09-21 | $2.46M 10-KT · filed 2026-09-21 | ||
| 2024-09-30 | $620.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $1.24M derived: sum of 2 quarters · filed 2025-11-04 | $1.84M 10-Q · filed 2025-11-04 | $56.39K derived: sum of 4 quarters · filed 2026-03-03 | ||
| 2024-06-30 | $615.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | $1.22M 10-Q · filed 2025-08-06 | -$563.61K derived: sum of 3 quarters · filed 2026-03-03 | $38.39K derived: sum of 4 quarters · filed 2026-03-03 | ||
| 2024-03-31 | $602.00K 10-Q · filed 2025-05-05 | -$1.18M derived: sum of 2 quarters · filed 2026-03-03 | -$576.61K derived: sum of 3 quarters · filed 2026-03-03 | $19.39K derived: sum of 4 quarters · filed 2026-03-03 | ||
| 2023-12-31 | -$1.78M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-03 | -$1.18M derived: sum of 2 quarters · filed 2026-03-03 | -$582.61K derived: sum of 3 quarters · filed 2026-03-03 | $2.39K 10-K · filed 2026-03-03 | $2.39M 10-K · filed 2024-03-11 | |
| 2023-09-30 | $602.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-05 | $1.20M derived: sum of 2 quarters · filed 2024-11-05 | $1.78M 10-Q · filed 2024-11-05 | $2.37M derived: sum of 4 quarters · filed 2025-02-27 | ||
| 2023-06-30 | $596.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-05 | $1.18M 10-Q · filed 2024-08-05 | $1.76M derived: sum of 3 quarters · filed 2025-02-27 | $2.35M derived: sum of 4 quarters · filed 2025-02-27 | ||
| 2023-03-31 | $585.00K 10-Q · filed 2024-05-09 | $1.17M derived: sum of 2 quarters · filed 2025-02-27 | $1.75M derived: sum of 3 quarters · filed 2025-02-27 | $2.33M derived: sum of 4 quarters · filed 2025-02-27 | ||
| 2022-12-31 | $584.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $1.17M derived: sum of 2 quarters · filed 2025-02-27 | $1.75M derived: sum of 3 quarters · filed 2025-02-27 | $2.32M 10-K · filed 2025-02-27 | ||
| 2022-09-30 | $585.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-02 | $1.16M derived: sum of 2 quarters · filed 2023-11-02 | $1.73M 10-Q · filed 2023-11-02 | $1.92M derived: sum of 4 quarters · filed 2024-03-11 | ||
| 2022-06-30 | $579.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-07 | $1.15M 10-Q · filed 2023-08-07 | $1.34M derived: sum of 3 quarters · filed 2024-03-11 | $1.39M derived: sum of 4 quarters · filed 2024-03-11 | ||
| 2022-03-31 | $568.00K 10-Q · filed 2023-05-11 | $757.00K derived: sum of 2 quarters · filed 2024-03-11 | $808.00K derived: sum of 3 quarters · filed 2024-03-11 | $1.12M derived: sum of 4 quarters · filed 2024-03-11 | ||
| 2021-12-31 | $189.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-11 | $240.00K derived: sum of 2 quarters · filed 2024-03-11 | $554.00K derived: sum of 3 quarters · filed 2024-03-11 | $705.00K 10-K · filed 2024-03-11 | ||
| 2021-09-30 | $51.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | $365.00K derived: sum of 2 quarters · filed 2022-11-08 | $516.00K 10-Q · filed 2022-11-08 | $732.00K derived: sum of 4 quarters · filed 2023-03-01 | ||
| 2021-06-30 | $314.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-08 | $465.00K 10-Q · filed 2022-08-08 | $681.00K derived: sum of 3 quarters · filed 2023-03-01 | $925.00K derived: sum of 4 quarters · filed 2023-03-01 | ||
| 2021-03-31 | $151.00K 10-Q · filed 2022-05-04 | $367.00K derived: sum of 2 quarters · filed 2023-03-01 | $611.00K derived: sum of 3 quarters · filed 2023-03-01 | $850.00K derived: sum of 4 quarters · filed 2023-03-01 | ||
| 2020-12-31 | $216.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-01 | $460.00K derived: sum of 2 quarters · filed 2023-03-01 | $699.00K derived: sum of 3 quarters · filed 2023-03-01 | $938.00K 10-K · filed 2023-03-01 | ||
| 2020-09-30 | $244.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-04 | $483.00K derived: sum of 2 quarters · filed 2021-11-04 | $722.00K 10-Q · filed 2021-11-04 | $961.00K derived: sum of 4 quarters · filed 2022-03-07 | ||
| 2020-06-30 | $239.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-09 | $478.00K 10-Q · filed 2021-08-09 | $717.00K derived: sum of 3 quarters · filed 2022-03-07 | $952.00K derived: sum of 4 quarters · filed 2022-03-07 | ||
| 2020-03-31 | $239.00K 10-Q · filed 2021-05-04 | $478.00K derived: sum of 2 quarters · filed 2022-03-07 | $713.00K derived: sum of 3 quarters · filed 2022-03-07 | $945.00K derived: sum of 4 quarters · filed 2022-03-07 | ||
| 2019-12-31 | $239.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-07 | $474.00K derived: sum of 2 quarters · filed 2022-03-07 | $706.00K derived: sum of 3 quarters · filed 2022-03-07 | $937.00K 10-K · filed 2022-03-07 | ||
| 2019-09-30 | $235.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-04 | $467.00K derived: sum of 2 quarters · filed 2020-11-04 | $698.00K 10-Q · filed 2020-11-04 | |||
| 2019-06-30 | $232.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-10 | $463.00K 10-Q · filed 2020-08-10 | ||||
| 2019-03-31 | $231.00K 10-Q · filed 2020-05-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |